New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2014
10:45 EDTMNKD, MNKDSummer Street's chief scientific officer holds analyst/industry conference call
Chief Scientific Officer Classen discusses Mannkind's inhaled insulin and whether it is approvable on an Analyst/Industry conference call to be held on March 26 at 11 am.
News For MNKD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
11:47 EDTMNKDMannKind's Afrezza lags behind in inhaled insulin market, The Street reports
The number of prescriptions written for MannKind's (MNKD) Afrezza is lagging behind in the diabetes market, reports The Street. This comes five months after Sanofi (SNY) launched the product. Afrezza is also under-performing Exubera, the first inhaled insulin launched by Pfizer (PFE) nine years ago. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use